Login Register
English
0

Cart

$ 0
OR
Catalog no Product name Protocol name IF Magazine title
ABP55480 Protection of Taohong Siwu Decoction on PC12 cells injured by oxygen glucose deprivation/reperfusion via mitophagy-NLRP3 inflammasome pathway in vitro(ABP55480-5.4) 5.4 Journal of Ethnopharmacology
A02020 SnRK2.4‐mediated phosphorylation of ABF2 regulates ARGININE DECARBOXYLASE expression and putrescine accumulation under drought stress(A02020-9.4) 9.4 Journal of Ethnopharmacology
A21010 HRP, Goat Anti-Mouse IgG SnRK2.4‐mediated phosphorylation of ABF2 regulates ARGININE DECARBOXYLASE expression and putrescine accumulation under drought stress(A21010-9.4) 9.4 New Phytologist
PRP100618 Rat TGF-β1 protein Norisoboldine, a Natural Isoquinoline Alkaloid, Inhibits Diaphyseal Fracture Healing in Mice by Alleviating Cartilage Formation(PRP100618-4.7) 4.7 Biomedicines
A21020 HRP, Goat Anti-Rabbit IgG SYNJ1 rescues motor functions in hereditary and sporadic Parkinson's disease mice by upregulating TSP-1 expression(A21020-2.7) 2.7 Behavioural Brain Research
A21020 HRP, Goat Anti-Rabbit IgG C-myc modulates the replication of RGNNV via glutamine-mediated ATP production in grouper fin cells(A21020-11.5) 11.5 Aquaculture and Fisheries
A21010 HRP, Goat Anti-Mouse IgG Berberine inhibits breast carcinoma proliferation and metastasis under hypoxic microenvironment involving gut microbiota and endogenous metabolites(A21010-9.3) 9.3 Pharmacological Research
A21020 HRP, Goat Anti-Rabbit IgG Berberine inhibits breast carcinoma proliferation and metastasis under hypoxic microenvironment involving gut microbiota and endogenous metabolites(A21020-9.3) 9.3 Pharmacological Research
BMU101-EN SuperKine™ West Pico PLUS Chemiluminescent Substrate Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic …(BMU101-EN-37.3) 37.3 Molecular Cancer
KTA2011 One-step TUNEL Apoptosis Assay Kit (Orange Fluorescence) inery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma(KTA2011-37.3) 37.3 Molecular Cancer